VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
Rozanne Arulanandam(Ottawa Hospital), John C. Bell(Ottawa Hospital), Jean‐Simon Diallo(University of Ottawa), Cory Batenchuk(Ottawa Hospital), Emma Burgess(Ottawa Hospital), Harold Atkins(University of Ottawa), Fernando A. Angarita(Methodist Hospital), Naomi De Silva(Ottawa Hospital), Grant A. Howe(University of Ottawa), Subash Sad(Institute for Biological Sciences), Jovian Tsang(Ottawa Hospital), Caroline J. Breitbach(University of Ottawa), J. Andrea McCart(Toronto General Hospital), Manijeh Daneshmand(University of Ottawa), Kathryn Ottolino‐Perry(University Health Network), Christina Addison(Ontario Institute for Cancer Research), Marie‐Claude Bourgeois‐Daigneault(Centre Hospitalier de l’Université de Montréal), Michael S. Huh(Ottawa Hospital), Sophie Cousineau(Ottawa Hospital), Leda Raptis(Queen's University), Fabrice Le Bœuf(Ottawa Hospital), Amelia Mottashed(Ottawa Hospital), Carolina S. Ilkow(Ottawa Hospital), Brian D. Lichty(McMaster University Medical Centre), Theresa Falls(Ottawa Hospital), David H. Kirn(Alameda Applied Sciences Corporation (United States)), David P. Conrad(Ottawa Hospital)
Cited by 104
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419